TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05363280: A Phase 2 Evaluation of the Safety and Efficacy of Veonetinib (AL8326) in ≥2nd Line Small Cell Lung Cancer (SCLC), Non Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Treatment

Sponsor: Advenchen Pharmaceuticals, LLC. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$12,058,200

Rescue Site Savings

+$7,946,400

Unlock Full NCT05363280 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05363280 Rescue Dossier →